Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31083259 | 1.00 | TLR4 (0.69) | TLR4ALDH1A1MAPTCA1CA2 | |
| SCHEMBL11718459 | 0.87 | TLR4 (0.68) | TLR4CYP19A1 | |
| SCHEMBL14401277 | 0.80 | TLR4 (0.50) | TLR4ALDH1A1MAPTMMP2 | |
| SCHEMBL11181948 | 0.70 | TLR4 (0.47) | TLR4ALDH1A1MAPTMMP2CYP19A1 | |
| SCHEMBL9609547 | 0.68 | TLR4 (0.50) | TLR4ALDH1A1MAPTKMT2A | |
| SCHEMBL5201714 | 0.68 | TLR4 (0.55) | TLR4MAPTCA1CA2CA4 | |
| SCHEMBL2577011 | 0.68 | TLR4 (0.42) | TLR4ALDH1A1MMP2CYP19A1 | |
| SCHEMBL11164098 | 0.67 | TLR4 (0.53) | TLR4ALDH1A1MAPT | |
| SCHEMBL11165151 | 0.67 | TLR4 (0.45) | TLR4ALDH1A1MAPTKMT2A | |
| SCHEMBL1964176 | 0.67 | TLR4 (0.48) | TLR4MAPTCA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9909073-B2 | Process of generating a renewable biofuel from a hydrotreated stream of condensed oxygenates | INAERIS TECHNOLOGIES, LLC (US) | 2018-03-06 | — | — | US | disclosed |
| US-9909073-B2 | Process of generating a renewable biofuel from a hydrotreated stream of condensed oxygenates | INAERIS TECHNOLOGIES, LLC (US) | 2018-03-06 | — | — | US | disclosed |
| US-9290423-B2 | Process of generating a renewable biofuel from a hydrotreated stream of condensed oxygenates | KIOR, LLC (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290423-B2 | Process of generating a renewable biofuel from a hydrotreated stream of condensed oxygenates | KIOR, LLC (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160010001-A1 | PROCESS OF GENERATING A RENEWABLE BIOFUEL FROM A HYDROTREATED STREAM OF CONDENSED OXYGENATES | MARD, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20160010001-A1 | PROCESS OF GENERATING A RENEWABLE BIOFUEL FROM A HYDROTREATED STREAM OF CONDENSED OXYGENATES | MARD, INC. | 2016-01-14 | — | — | US | disclosed |
| US-9200209-B2 | Process of generating a renewable biofuel from a hydrotreated stream of condensed oxygenates | KIOR, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9200209-B2 | Process of generating a renewable biofuel from a hydrotreated stream of condensed oxygenates | KIOR, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140142355-A1 | PROCESS OF GENERATING A RENEWABLE BIOFUEL FROM A HYDROTREATED STREAM OF CONDENSED OXYGENATES | KIOR, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142354-A1 | Process of Generating a Renewable Biofuel From a Hydrotreated Stream of Condensed Oxygenates | KIOR, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20110160309-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | NEREUS PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| EP-2319621-A2 | Base stable ionic liquids | The Queen's University of Belfast (GB) | 2011-05-11 | — | — | EP | disclosed |
| EP-2286915-A2 | IONIC LIQUIDS WITH A CATION COMPRISING A BASIC MOIETY | The Queen's University of Belfast (GB) | 2011-02-23 | — | — | EP | disclosed |
| EP-1591437-B1 | Interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators | NEREUS PHARMACEUTICALS INC (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090270248-A1 | Basic ionic liquids | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270248-A1 | Basic ionic liquids | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090216015-A1 | Base Stable Ionic Liquids | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20090216015-A1 | Base Stable Ionic Liquids | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2009-08-27 | — | — | US | disclosed |
| US-7342125-B2 | Method of treating inflammation with acanthoic acid derivatives | NEREUS PHARMACEUTICALS, INC. (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1178952-B1 | NOVEL INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS, SYNTHESES OF SAID MODULATORS AND METHODS OF USING SAID MODULATORS | NEREUS PHARMACEUTICALS INC (US) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160010001-A1 | PROCESS OF GENERATING A RENEWABLE BIOFUEL FROM A HYDROTREATED STREAM OF CONDENSED OXYGENATES | CBR3, C5, CBR1 | TLR4 3445/4885ALDH1A1 1130/4885MAPT 2569/4885 |
| US-20140142354-A1 | Process of Generating a Renewable Biofuel From a Hydrotreated Stream of Condensed Oxygenates | CBR3, C5, CBR1 | TLR4 3445/4885ALDH1A1 1130/4885MAPT 2569/4885 |
| US-20110160309-A1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | IL1A, IL1B, TNF | TLR4 593/4885ALDH1A1 2662/4885MAPT 4689/4885 |
| US-20090216015-A1 | Base Stable Ionic Liquids | BRAF, TIAL1, HPRT1 | TLR4 4457/4885ALDH1A1 2477/4885MAPT 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.